# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN
- Date: 2026-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Sixteen-week review of hormone recovery and depression treatment. **S**

## History of present illness

Mr. Turing returns eight weeks after starting bupropion XL 150 mg. The nurse telephone check planned for two weeks after the start did not happen: he was abroad at a conference, two calls went unanswered, and no further call was booked. He had a dry mouth and some difficulty falling asleep in the first week, which settled when he took the tablet earlier in the morning, and no headache, tremor, or restlessness. He has missed no doses. His mood is clearly better: he enjoys running again, at about 35 km a week, and has started working on a new problem with real pleasure. He sleeps about seven hours. Libido and erections are back to his usual. He has had fourteen psychotherapy sessions. The breast tissue is smaller and tender only when pressed. He has had no suicidal thoughts. **S**

| Element | Detail |
|---|---|
| Missed contact | Two-week nurse call after starting bupropion not completed |
| Bupropion | Dry mouth and trouble falling asleep in week one, now settled; no missed doses |
| Sexual function | Libido and erections back to his usual |
| Running | About 35 km a week |
| Safety | No suicidal thoughts |
| PHQ-9 | 7, down from 15 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Breast | Negative | Tender only when pressed; no discharge |
| Neurological | Negative | No headache, tremor, or seizures |
| Cardiovascular | Negative | No palpitations |
| Psychiatric | Positive | Mild residual low mood on some days; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**
- Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 69.3 kg; BMI 21.9 kg/m². All vital signs are synthetic.

PHQ-9: 7; Total testosterone: 452 ng/dL; LH: 4.8 m[IU]/mL; FSH: 5.2 m[IU]/mL; Hemoglobin: 14.4 g/dL. All results are synthetic.

## Change since baseline

- PHQ-9: 15 at baseline, 7 at this visit **S**
- Total testosterone: 112 ng/dL (low) at baseline, 452 ng/dL at this visit **S**
- LH: 0.3 m[IU]/mL (low) at baseline, 4.8 m[IU]/mL at this visit **S**
- FSH: 0.4 m[IU]/mL (low) at baseline, 5.2 m[IU]/mL at this visit **S**
- Hemoglobin: 13 g/dL (low) at baseline, 14.4 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; brisk |
| Breast | Examined with his agreement: glandular tissue about 2.5 cm behind the left nipple and 1.5 cm behind the right, tender only on firm pressure; no discrete mass |
| Mental status | Alert; mood "much more like myself"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-induced hypogonadotropic hypogonadism, resolved** (E23.1). Testosterone 452 ng/dL with LH 4.8 and FSH 5.2 mIU/mL: the axis has recovered without treatment, about four months after the last estrogen injection. Hemoglobin 14.4 g/dL. **S**
   - No further hormone tests needed except testosterone and estradiol once more at six months.
   - Bone density scan not needed, as the hypogonadism lasted under six months.
2. **Bilateral gynecomastia, improving** (N62). Continuing to shrink. **S**
   - Continue watchful waiting; review at six months.
3. **Major depressive disorder, single episode, responding** (F32.1). PHQ-9 7, down 53 percent from 15: a response, not yet remission. Bupropion is well tolerated; blood pressure 124/78 mmHg. Suicide risk remains low. **S**
   - Continue bupropion XL 150 mg; psychotherapy to the end of the course of 16 sessions, then monthly.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Glandular tissue about 2.5 cm on the left and 1.5 cm on the right, tender only on firm pressure; no discrete mass |
| Laboratory | Testosterone, LH, and FSH | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Testosterone 452 ng/dL, LH 4.8 and FSH 5.2 mIU/mL: all normal; recovery complete |
| Laboratory | Hemoglobin while testosterone is low | With each hormone check until normal | Completed today | 14.4 g/dL |
| Imaging | Bone density (DXA) | If hypogonadism persists beyond six months or a fragility fracture occurs | Not indicated | The axis recovered within about four months of the last estrogen dose |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 7, down 53 percent from 15: response; remission not yet reached |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | Antidepressant tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Deferred | Not done, a deviation from the protocol: the nurse telephone check two weeks after bupropion was started, which was also to supply the monthly PHQ-9, was not completed after two unanswered calls while he was abroad, and no further call was booked, leaving eight weeks without a score. No harm resulted judging by today's review: the early insomnia and dry mouth settled, blood pressure is 124/78 mmHg, and there were no suicidal thoughts. Corrective action: a missed safety call is now rebooked within two days and flagged to Dr. Hallam if it cannot be completed |
| Medication safety | Adherence, adverse effects, and blood pressure on bupropion | Every visit during active treatment | Completed today | No missed doses; early dry mouth and insomnia settled; blood pressure 124/78 mmHg |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Fourteen sessions; sleep about seven hours; running about 35 km a week |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |

## Goal progress

- Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy. Outcome by 2026-08-04: Testosterone 452 ng/dL with normal LH and FSH at sixteen weeks. **S**
- Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him. In progress; target 2026-10-06. **S**
- Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5). In progress; target 2026-10-06. **S**
- Back to running about 40 km a week and changing at his club again. In progress; target 2026-10-06. **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012), Endocrine Society
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Six-month review in two months with testosterone, estradiol, vitamin D, and PHQ-9. **S**
- Next scheduled visit 2026-10-06: six-month review of gynecomastia and depression in continuation treatment. **S**
